Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Operating Leases: 2019-2025

Historic Operating Leases for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $6.2 million.

  • UroGen Pharma's Operating Leases rose 501.83% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 501.83%. This contributed to the annual value of $1.7 million for FY2024, which is 95.85% up from last year.
  • As of Q3 2025, UroGen Pharma's Operating Leases stood at $6.2 million, which was up 82.86% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Operating Leases registered a high of $6.2 million during Q3 2025, and its lowest value of $398,000 during Q4 2021.
  • In the last 3 years, UroGen Pharma's Operating Leases had a median value of $1.9 million in 2023 and averaged $2.3 million.
  • As far as peak fluctuations go, UroGen Pharma's Operating Leases tumbled by 73.41% in 2021, and later spiked by 534.92% in 2022.
  • Over the past 5 years, UroGen Pharma's Operating Leases (Quarterly) stood at $398,000 in 2021, then surged by 534.92% to $2.5 million in 2022, then tumbled by 66.60% to $844,000 in 2023, then skyrocketed by 95.85% to $1.7 million in 2024, then skyrocketed by 501.83% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $3.4 million for Q2 2025, and $2.8 million during Q1 2025.